Patent US4199586A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4199586A Expired / Lapsed US ⏱️ 0.0 years remaining

Di-(lower-alkyl) N-[1,2-dihydro-2-oxo-5-(pyridinyl)-3-pyridinyl]amino-methylanemalonates

Assignee: Aventis Pharmaceuticals Inc
•
Filing: 1978-08-28
•
Granted: 1980-04-22
•
Expires: 1998-08-28
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds useful as cardiotonic agents are 1-R-3-Q-5-PY-2(1H)-pyridinones (I) where R is hydrogen, lower-alkyl or lower-hydroxyalkyl, Q is amino (preferred), lower-alkylamino, di-(lower-alkyl)amino or NHAc, Ac is lower-alkanoyl or lower-carbalkoxy, and PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents. The corresponding compounds where Q is nitro, carbamyl, cyano, halo or hydrogen are useful as intermediates and those where Q is hydrogen or cyano also are useful as cardiotonic agents. Said compounds are prepared: by reacting α-PY-β-(R 1 R 2 N)acrolein (II) with malonamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinamide (Ia) and reacting Ia with a reagent capable of converting carbamyl to amino to produce 3-amino-5-PY-2(1H)-pyridinone (Ib); by reacting II or α-PY-malonaldehye (II') with α-cyanoacetamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinonitrile (III) and partially hydrolyzing III to produce Ia; and, by heating 1,2-dihydro-2-oxo-5-PY-nicotininc acid (IV) with a mixture of concentrated sulfuric acid and concentrated nitric acid to produce 3-nitro-5-PY-2(1H)-pyridinone (Ic) and then either reducing Ic to produce Ib or first reacting Ic with an alkylating agent to produce 1-R'-3-nitro-5-PY-2(1H)-pyridinone (Id) and reducing Ic to produce 1-R'-3-amino-5-PY-2(1H)-pyridinone (Ib) where R' is lower-alkyl or lower-hydroxyalkyl. Other derivatives of I where Q is amino are shown.

Inventors

  • 👤 George Y. Lesher
  • 👤 Chester J. Opalka, Jr.

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-08 01:00
CPC Classifications
C; C07; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/24; C07D213/44; C07D213/53; C07D213/36; C07D213/38; C07D213/46; C07D213/48; C07D213/60; C07D213/62; C07D213/63; C07D213/64; C07D213/72; C07D213/73; C07D213/74; C07D213/75; C07D213/78; C07D213/79; C07D213/80; C07D213/81; C07D213/82; C07D213/84; C07D213/85

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 27 words
Di-(lower-alkyl) N-(1,2-dihydro-2-oxo-5-PY-3-pyridinyl)aminomethylenemalonate where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 2
Dependent Claim 27 words
Di-(lower-alkyl) N-(1,2-dihydro-2-oxo-5-PY-3-pyridinyl)aminomethylenemalonate where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 3
Dependent Claim 14 words
Dietnhyl N-[1,2-dihydro-2-oxo-5-(4-pyridinyl)-3-pyridinyl]aminomethylenemalonate according to claim 1 where PY is 4-pyridinyl and lower-alkyl is ethyl.
Claim 4
Dependent Claim 53 words
A cardiotonic composition for increasing cardiac contractility, said composition comprising a pharmaceutically-acceptable inert carrier and, as the active component thereof, an effective amount of a cardiotonic di-(lower-alkyl) N-[1,2-dihydro-2-oxo-5-PY-3-pyridinyl]aminomethylenemalonate, where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 5
Dependent Claim 53 words
A cardiotonic composition for increasing cardiac contractility, said composition comprising a pharmaceutically-acceptable inert carrier and, as the active component thereof, an effective amount of a cardiotonic di-(lower-alkyl) N-[1,2-dihydro-2-oxo-5-PY-3-pyridinyl]aminomethylenemalonate, where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 6
Dependent Claim 13 words
A composition according to claim 3 where the active component is diethyl N-[1,2-dihydro-2-oxo-5-(4-pyridinyl)-3-pyridinyl]aminomethylenemalonate.
Claim 7
Independent Claim 55 words
The method for increasing cardiotonic contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient an effective amount of a cardiotonic di-(lower-alkyl) N-[1,2-dihydro-2-oxo-5-PY-3-pyridinyl]aminomethylenemalonate, where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 8
Independent Claim 55 words
The method for increasing cardiotonic contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient an effective amount of a cardiotonic di-(lower-alkyl) N-[1,2-dihydro-2-oxo-5-PY-3-pyridinyl]aminomethylenemalonate, where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 9
Dependent Claim 14 words
The method according to claim 5 where the cardiotonic active compound is diethyl N-[1,2-dihydro-2-oxo-5-(4-pyridinyl)-3-pyridinyl]aminomethylenemalonate.

References Cited (Backward Citations)

GB1322318A Cited
DE2125310A1 Cited
US3838155A Cited
US4072746A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1983-04-22 1983-10-22 1984-04-22 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1987-04-22 1987-10-22 1988-04-22 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1991-04-22 1991-10-22 1992-04-22 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag